
KRRO Stock Forecast & Price Target
KRRO Analyst Ratings
Bulls say
Korro Bio is poised for potential success with KRRO-121, as it has a strong pipeline of disease-modifying treatments for rare and prevalent diseases. The company's innovative approach to RNA editing technology offers a precise and tunable solution to treat a range of disorders. Additionally, Korro Bio has a clear clinical and regulatory path for their therapies, giving investors confidence in their potential success.
Bears say
Korro Bio is a clinical-stage biopharmaceutical company with a portfolio of programs that are designed to harness the body's natural RNA editing process to treat rare and highly prevalent diseases. Their lead asset, KRRO-121, is a GalNAc-ASO designed to reduce hyperammonemia in urea cycle disorder (UCD) and hepatic encephalopathy (HE) by stabilizing glutamine synthetase (GS). While the company has presented compelling preclinical data and has a clear regulatory path established for HE, there are financial risks associated with their development stage and the need for additional funding. Additionally, the company's lead product may face challenges in achieving widespread adoption due to the difficulty in managing UCD and potential competition from other treatments. As such, the company's financial outlook is uncertain and it may face challenges in achieving their projected targets.
This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KRRO Analyst Forecast & Price Prediction
Start investing in KRRO
Order type
Buy in
Order amount
Est. shares
0 shares